| A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer RD Kim, V Chung, OB Alese, BF El-Rayes, D Li, TE Al-Toubah, MJ Schell, ... JAMA oncology 6 (6), 888-894, 2020 | 421 | 2020 |
| Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms IH Sahin, M Akce, O Alese, W Shaib, GB Lesinski, B El-Rayes, C Wu British journal of cancer 121 (10), 809-818, 2019 | 332 | 2019 |
| Appendiceal mucinous neoplasms: diagnosis and management WL Shaib, R Assi, A Shamseddine, OB Alese, C Staley III, B Memis, ... The oncologist 22 (9), 1107-1116, 2017 | 234 | 2017 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The Lancet Oncology 24 (12), 1399-1410, 2023 | 193 | 2023 |
| Prevalence of skin diseases in Ibadan, Nigeria AO Ogunbiyi, OOM Daramola, OO Alese International journal of dermatology 43 (1), 31-36, 2004 | 182 | 2004 |
| The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, ... Cancer 125 (1), 127-134, 2019 | 148 | 2019 |
| Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, ... BMC cancer 19, 1-8, 2019 | 115 | 2019 |
| A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer AM Monjazeb, A Giobbie-Hurder, A Lako, EM Thrash, RC Brennick, ... Clinical Cancer Research 27 (9), 2470-2480, 2021 | 84 | 2021 |
| US cancer centers of excellence strategies for increased inclusion of racial and ethnic minorities in clinical trials JM Regnante, NA Richie, L Fashoyin-Aje, M Vichnin, M Ford, UB Roy, ... Journal of oncology practice 15 (4), e289-e299, 2019 | 82 | 2019 |
| Contemporary management of borderline resectable and locally advanced unresectable pancreatic cancer WL Shaib, A Ip, K Cardona, OB Alese, SK Maithel, D Kooby, J Landry, ... The oncologist 21 (2), 178-187, 2016 | 73 | 2016 |
| A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC). RD Kim, DW Kim, OB Alese, D Li, N Shah, MJ Schell, JM Zhou, V Chung Journal of Clinical Oncology 37 (15_suppl), 4097-4097, 2019 | 71* | 2019 |
| HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy GP Nagaraju, OB Alese, J Landry, R Diaz, BF El-Rayes Oncotarget 5 (20), 9980, 2014 | 67 | 2014 |
| Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy MA Bilen, DJ Martini, Y Liu, JM Shabto, JT Brown, M Williams, AI Khan, ... The oncologist 25 (3), e528-e535, 2020 | 61 | 2020 |
| High‐grade gastrointestinal neuroendocrine carcinoma management and outcomes: A national cancer database study OB Alese, R Jiang, W Shaib, C Wu, M Akce, M Behera, BF El‐Rayes The oncologist 24 (7), 911-920, 2019 | 61 | 2019 |
| Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials DJ Martini, MR Kline, Y Liu, JM Shabto, MA Williams, AI Khan, C Lewis, ... Cancer 126 (3), 575-582, 2020 | 60 | 2020 |
| Abstract CT116: BMS-986205, an optimized indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination … LL Siu, K Gelmon, Q Chu, R Pachynski, O Alese, P Basciano, J Walker, ... Cancer Research 77 (13_Supplement), CT116-CT116, 2017 | 57 | 2017 |
| Role of adiponectin in obesity related gastrointestinal carcinogenesis GP Nagaraju, S Aliya, OB Alese Cytokine & growth factor reviews 26 (1), 83-93, 2015 | 57 | 2015 |
| Aquaporins: Their role in gastrointestinal malignancies GP Nagaraju, R Basha, B Rajitha, OB Alese, A Alam, S Pattnaik, ... Cancer letters 373 (1), 12-18, 2016 | 56 | 2016 |
| Impact of sarcopenia, BMI, and inflammatory biomarkers on survival in advanced hepatocellular carcinoma treated with anti-PD-1 antibody M Akce, Y Liu, K Zakka, DJ Martini, A Draper, OB Alese, WL Shaib, C Wu, ... American Journal of Clinical Oncology 44 (2), 74-81, 2021 | 54 | 2021 |
| Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer B Rajitha, GP Nagaraju, WL Shaib, OB Alese, JP Snyder, M Shoji, ... Molecular carcinogenesis 56 (1), 288-299, 2017 | 53 | 2017 |
